Transforming Concussion Care with Innovative Intranasal Delivery
The first potential FDA-approved therapy for concussion.
Oragenics is pioneering brain-first neurotherapeutics, developing ONP-002—a first-in-class intranasal neurosteroid that targets the biology of brain injury, not just the symptoms. With Phase 1 complete and Phase 2 trials underway, we’re advancing toward a new standard of care for the 69 million people who suffer concussions each year.
It’s Not A Medicine. It’s A Movement.
Current concussion treatment is limited to rest and symptom management—with no way to address the underlying injury. Just hope.
We’re changing that.
ONP-002 is designed to address the underlying biology of brain injury, reducing inflammation, oxidative stress, and swelling at the source. Delivered through our proprietary intranasal device, ONP-002 bypasses the blood-brain barrier for rapid, targeted action.
Oragenics is building a movement around Brain-First Recovery™—transforming how patients, clinicians, and healthcare systems approach neurological trauma. Phase 1 trials demonstrated excellent safety with zero serious adverse events.
Concussions Annually Worldwide
Total Addressable Market
FDA Treatments for Concussion
